Zai Lab to present new PRIME subgroup analysis for niraparib in ovarian cancer at 2022 ASCO annual conference.
Zai Lab Limited announced the presentation of a new subgroup data analysis from the Phase III PRIME study (NCT03709316) for niraparib in women in China with ovarian cancer at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7, 2022.
Since patient response to chemotherapy is associated with ovarian cancer prognosis, this subgroup analysis explores the treatment effect of niraparib maintenance therapy in patients with advanced ovarian cancer based on first-line platinum-based chemotherapy response.
This presentation highlights a new prespecified subgroup analysis examining 384 newly diagnosed stage III or IV ovarian cancer patients enrolled in the PRIME study, who also experienced a complete response (CR) or partial response (PR) to first-line platinum-based chemotherapy. The median progression-free survival was measured at 29.4 months for niraparib vs 8.3 months for placebo (HR=0.45; 95% CI, 0.32–0.61; P<0.001) in the complete response group. in the partial response group, the results showed median progression-free survival of 19.3 months for niraparib versus 8.3 months for placebo (hr="0.45;" 95% ci, 0.23–0.86; p="0.014)." the safety profile of niraparib was consistent with previous clinical trials, with no new safety issues identified in this subgroup analysis.></0.001)>
Details of this virtual poster presentation at ASCO 2022 are as follows: Title: "Efficacy of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer in phase 3 PRIME study: A subgroup analysis by response to first-line platinum-based chemotherapy".. Abstract number: 5551.Session Date and Time: Saturday, June 4, 2022, 1:15 PM-4:15 PM CDT Presenter: Dr. Rutie Yin, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, China.
Related news and insights
The FDA has approved crizotinib (Xalkori) for the treatment of unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT) in adults and children over 1 year of age.
Bayer announced the FDA has approved a supplemental New Drug Application (sNDA) for the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) with docetaxel for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Myovant Sciences and Pfizer Inc. announced that the FDA)has approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months.